Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AZD6244 (Selumetinib)

Last Updated: 02/16/18

Status: Currently a NF2 Clinical Trial


Chemical Structure, selumetinib

Trade Name: N/A
Synonyms: AZD 6244, 606143-52-6, AZD6244, AZD-6244,
ARRY-142886, CHEMBL1614701, NCGC00189073-01,
PubChem21092, Selumetinib (USAN/INN)
Pharmaceutical Company: N/A
Protein Target: MAPK/ERK Pathway
Legal Status: ℞ - Prescription/Under Clinical Trial
Administered By: Unknown if IV or Pill
Formula: C17H15BrClFN4O3
ChemSpider: 8303141 (Accessed: 2018)
PubChem: CID 10127622

Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC). - Wikipedia

Treatment Information

UK Treatments: The role of insulin-like growth factors signaling in merlin-deficient human schwannomas


Also Treatment For

  • Thyroid Cancer
  • Melanoma
  • Colorectal Cancer
  • Ovarian Cancer

Patents

Top 5 of 19 Treatments
Patent # Date Title
US20100260714A1 6-4-2012 COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF
US20100267793A1 6-4-2012 METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20100261718A1 5-14-2012 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20100261717A1 8-22-2011 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20100267710A1 7-4-2011 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS